SnapshotUpdated April 2026
Drugs Going Generic Soon
Expensive brand-name drugs with upcoming patent expirations
10 brand-name drugs have upcoming patent expirations that could lead to cheaper generic alternatives.
| # | Name | Metric |
|---|---|---|
| 1 | Januvia Patent expires: 2026-07-17, Merck | $2.7B |
| 2 | Trintellix Patent expires: 2026-09-30, Takeda | $1.1B |
| 3 | Entresto Patent expires: 2026-11-11, Novartis | $4.8B |
| 4 | Revlimid Patent expires: 2027-03-15, Bristol-Myers Squibb | $7.8B |
| 5 | Pomalyst Patent expires: 2027-04-09, Bristol-Myers Squibb | $3.3B |
| 6 | Trulicity Patent expires: 2027-09-18, Eli Lilly | $4.2B |
| 7 | Gilenya Patent expires: 2027-09-22, Novartis | $1.4B |
| 8 | Jakafi Patent expires: 2027-11-16, Incyte | $2.7B |
| 9 | Keytruda Patent expires: 2028-06-28, Merck | $7.2B |
| 10 | Basaglar Patent expires: 2028-12-16, Eli Lilly | $845.0M |
10 brand-name drugs have upcoming patent expirations that could lead to cheaper generic alternatives.
Frequently Asked Questions
This report is auto-generated from real public data sources. Entities are ranked by their key metrics and the most notable changes and extremes are highlighted.
The underlying data is refreshed on a regular schedule. This report was generated from the most recent available data (last updated April 2026).
The primary metric varies by report type. It may represent a score, dollar amount, rate, or count depending on what the report is measuring.
Source: CMS Medicare Part D Spending, 2026.